In the KEYNOTE-051 study of pembrolizumab in patients with PD-L1-positive tumors, 17 of 154 patients (11%) experienced a complete response/PR (nine with Hodgkin lymphoma and eight with a variety of pediatric solid tumors)3. Here, CD274 is linked to Hodgkins lymphoma.